

## **Abénex and Cisbio's management announce the sale of Cisbio Bioassays to PerkinElmer to open a new phase in the development of the company**

**Paris, April 26, 2019.** Abenex and Cisbio's management are delighted to announce the acquisition by PerkinElmer from Abénex of Cisbio Bioassays, a leading custom assay service provider with a broad portfolio of Homogeneous Time Resolved Fluorescence (HTRF)<sup>®</sup> kits and reagents.

Founded in 1974, and headquartered in Codolet, France, Cisbio has more than 200 employees. Cisbio develops, manufactures, and markets high quality kits and reagents for the life sciences and drug discovery markets. After a successful ramp up over the last four years as a standalone company, Cisbio's management and Abénex were looking for the next development step to find a partner which could support Cisbio's ambitious growth plan.

Cisbio's portfolio will expand PerkinElmer's current offerings for life sciences researchers. Specifically, Cisbio's market leading and proprietary HTRF screening technology will ideally complement PerkinElmer's customers' upstream workflows such as target identification and characterization, along with downstream applications such as lead optimization and validation.

*"This operation represents a promising match for our company," declared Joseph Jammal, CEO of Cisbio. "This will enable us to serve even better the scientific community with a best-in-class reagent and custom assay offer based on no-wash detection assays."*

### **About Abénex ([www.abenex.com](http://www.abenex.com))**

Founded in 1992, Abénex is a historical player in French private equity market, specialized in growth and buyout transactions both as a minority and majority shareholder. Independent for more than 10 years, Abénex operates on three segments of private equity: Smallcaps, Midcaps and Real-estate.

On Small and Midcaps segments, Abénex is a long-term investor partnering with entrepreneurs and founding families, and operationally-involved in growth and operational optimization projects. Abénex is committed to the Management team's success, providing them with a fully dedicated operational team to support their projects of transformation and external growth strategy. Abénex invests in SMEs valued up to €50m in Smallcaps and between €50m and €500m in Midcaps.

Abénex' real-estate team invests in Value-Add projects of up to €80m of asset value as well as in Core+ opportunities with an asset value in excess of €50m, notably in the retail, logistics, serviced residences and education sectors.

The team is composed of 30 professionals with demonstrated and renowned expertise, located in Paris and Lyon.

Abénex is approved by the AMF (Autorité des Marchés Financiers) to manage FPCI (Fonds Professionnels de Capital Investissement) and OPCI (Organismes de Placement Collectif Immobilier) funds.

## **Deal Participants**

**Acquirer** : PerkinElmer

**Acquirer's advisor** : Hogan Lovells LLP (Jean-Marc Franceschi, Florian Tranchecoste, Sophie Han)

**Sellers** : Management (Joseph Jammal and management team), Abénex (Antoine Schouman, Johann Dupont, Vincent Gouedard)

## **Sellers' advisors**

M&A: Edmond de Rothschild (Arnaud Petit, Laure Klein, Mohamed R'Tel Bennani)

Legal: DLA Piper (Xavier Norlain, Julia Elkael, Alexis Orlando)

Management: Taylor Wessing (Laurence Lapeyre, Dalila Mabrouki)

Financial vendor due diligence: Eight Advisory (Lionnel Gérard, Christophe Puissegur, Valérie Jacquard)

Legal, tax and social due diligence: Fidal (Xavier Houard, Anne Frechette-Kerbrat, Albane Eglinger)

Insurance: Zurich Insurance (Charles de Mombynes), SIACI Saint Honoré (Eric Remus, Maxime Bonduelle)